Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Marshall B, Elam"'
Autor:
Timothy J Garrett, Michelle A Puchowicz, Edwards A Park, Qingming Dong, Gregory Farage, Richard Childress, Joy Guingab, Claire L Simpson, Saunak Sen, Elizabeth C Brogdon, Logan M Buchanan, Rajendra Raghow, Marshall B Elam
Publikováno v:
PLoS ONE, Vol 18, Iss 12, p e0294498 (2023)
BackgroundBetween 5-10% of patients discontinue statin therapy due to statin-associated adverse reactions, primarily statin associated muscle symptoms (SAMS). The absence of a clear clinical phenotype or of biomarkers poses a challenge for diagnosis
Externí odkaz:
https://doaj.org/article/e2f188c7a2cd4b38a82684bcf7f360b7
Autor:
Qingming Dong, Michael S. Kuefner, Xiong Deng, Dave Bridges, Edwards A. Park, Marshall B. Elam, Rajendra Raghow
Publikováno v:
Biology of Sex Differences, Vol 9, Iss 1, Pp 1-15 (2018)
Abstract Background Patients with metabolic syndrome, who are characterized by co-existence of insulin resistance, hypertension, hyperlipidemia, and obesity, are also prone to develop non-alcoholic fatty liver disease (NAFLD). Although the prevalence
Externí odkaz:
https://doaj.org/article/0ea7f98199934454960e629c36c71b38
Autor:
Michael S. Kuefner, Kevin Pham, Jeanna R. Redd, Erin J. Stephenson, Innocence Harvey, Xiong Deng, Dave Bridges, Eric Boilard, Marshall B. Elam, Edwards A. Park
Publikováno v:
Journal of Lipid Research, Vol 58, Iss 9, Pp 1822-1833 (2017)
Secretory phospholipase A2 group IIA (PLA2G2A) is a member of a family of secretory phospholipases that have been implicated in inflammation, atherogenesis, and antibacterial actions. Here, we evaluated the role of PLA2G2A in the metabolic response t
Externí odkaz:
https://doaj.org/article/2523d5116bc348908f7cd22c40248d7f
Autor:
Aruna, Das Pradhan, Robert J, Glynn, Jean-Charles, Fruchart, Jean G, MacFadyen, Elaine S, Zaharris, Brendan M, Everett, Stuart E, Campbell, Ryu, Oshima, Pierre, Amarenco, Dirk J, Blom, Eliot A, Brinton, Robert H, Eckel, Marshall B, Elam, João S, Felicio, Henry N, Ginsberg, Assen, Goudev, Shun, Ishibashi, Jacob, Joseph, Tatsuhiko, Kodama, Wolfgang, Koenig, Lawrence A, Leiter, Alberto J, Lorenzatti, Boris, Mankovsky, Nikolaus, Marx, Børge G, Nordestgaard, Dénes, Páll, Kausik K, Ray, Raul D, Santos, Handrean, Soran, Andrey, Susekov, Michal, Tendera, Koutaro, Yokote, Nina P, Paynter, Julie E, Buring, Peter, Libby, Paul M, Ridker, Maureen, McClelland
Publikováno v:
Das Pradhan, A, Glynn, R J, Fruchart, J C, MacFadyen, J G, Zaharris, E S, Everett, B M, Campbell, S E, Oshima, R, Amarenco, P, Blom, D J, Brinton, E A, Eckel, R H, Elam, M B, Felicio, J S, Ginsberg, H N, Goudev, A, Ishibashi, S, Joseph, J, Kodama, T, Koenig, W, Leiter, L A, Lorenzatti, A J, Mankovsky, B, Marx, N, Nordestgaard, B G, Páll, D, Ray, K K, Santos, R D, Soran, H, Susekov, A, Tendera, M, Yokote, K, Paynter, N P, Buring, J E, Libby, P & Ridker, P M 2022, ' Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. ', New England Journal of Medicine, vol. 387, no. 21, pp. 1923-1934 . https://doi.org/10.1056/NEJMoa2210645
Background High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated
Autor:
Marshall B Elam, Gipsy Majumdar, Khyobeni Mozhui, Ivan C Gerling, Santiago R Vera, Hannah Fish-Trotter, Robert W Williams, Richard D Childress, Rajendra Raghow
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0181308 (2017)
Statins, the 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors, are widely prescribed for treatment of hypercholesterolemia. Although statins are generally well tolerated, up to ten percent of statin-treated patients experience myalgia sympt
Externí odkaz:
https://doaj.org/article/f656a1c7cac74a59ac6269e67cfb387b
Autor:
Luis G. Aguayo, Marium Ahmed, Mohamed H. Ahmed, Musaab Ahmed, Hélio M.T. Albuquerque, Alicia Alonso, Rana Ashkar, Fodil Azzaz, Carlos J. Baier, Francisco J. Barrantes, Małgorzata Bednarska-Makaruk, Andrew S. Bell, Asier Benito-Vicente, Michael F. Brown, Anna N. Bukiya, Carlos F. Burgos, Henri Chahinian, Waranya Chatuphonprasert, Parkson Lee-Gau Chong, Arrigo F.G. Cicero, Ivan R. Cincione, Tatiana M. Clemente, George A. Cook, Zoe Cournia, Coralie Di Scala, Milka Doktorova, Fathima T. Doole, Alex M. Dopico, Alexandros A. Drosos, Hong Du, Marshall B. Elam, Isabella Ellinger, Jacques Fantini, Filipe Ferrari, Unai Galicia-Garcia, Aritz B. García-Arribas, Stacey D. Gilk, Félix M. Goñi, Juliana Gonzalez-Sanmiguel, Gregory A. Grabowski, Sudipta Gupta, Tina Herfel, DanRong Hu, Juyang Huang, Shifa Jebari-Benslaiman, Qiu-Xing Jiang, Samantha Karr, George Khelashvili, Sofia Kiriakidi, Tamas Kovacs, Teshani Kumarage, Claude K. Lardinois, Asier Larrea-Sebal, Irena Levitan, Hanxuan Li, Wei Li, Falk W. Lohoff, Agnieszka Ługowska, Cesar Martin, Vítor M. Martins, Thomas Mavromoustakos, Mark T. Mc Auley, Dushyant Mital, Bob M. Moore, Amy E. Morgan, Ole G. Mouritsen, Steven Mysiewicz, Kelsey C. North, Emma M. O’Connell, Marta Pasenkiewicz-Gierula, ZhiYong Qian, Jorge P. Roa, Avia Rosenhouse-Dantsker, Clementina M.M. Santos, Artur M.S. Silva, Alexandria Slayden, Ghada A. Soliman, Natalia Stein, Ricardo Stein, Witold K. Subczynski, István P. Sugár, Lajos Szente, Kepa B. Uribe, Zoltan Varga, Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Francine K. Welty, Justyna Widomska, Nouara Yahi, Zdenek Zadak, Florina Zakany
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b40991fd39b691490fd3a3998572c24a
https://doi.org/10.1016/b978-0-323-85857-1.09991-0
https://doi.org/10.1016/b978-0-323-85857-1.09991-0
Autor:
Jordan Fulcher, Anthony C Keech, Anosh Sivashanmugarajah, David R. Sullivan, Alicia J. Jenkins, Marshall B. Elam
Publikováno v:
Internal Medicine Journal. 49:1081-1091
Hyperlipidaemia is a major risk factor for cardiovascular morbidity and mortality. 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors ('statins') are first-line therapies for hyperlipidaemia. For each 1.0 mmoL/L reduction in low-density lipop
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1864:1145-1156
Lipid homeostasis is critically dependent on the liver. Hepatic genes involved in lipid biosynthesis are controlled by combinatorial actions of multiple transcription factors that include three sterol regulatory element binding proteins (SREBPs), car
Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat
Autor:
Marshall B. Elam, Henry G. Wilcox, Lauren M. Cagen, Xiong Deng, Rajendra Raghow, Poonam Kumar, Murray Heimberg, James C. Russell
Publikováno v:
Journal of Lipid Research, Vol 42, Iss 12, Pp 2039-2048 (2001)
The corpulent JCR:LA-cp rat (cp/cp) is a useful model for study of the metabolic consequences of obesity and hyperinsulinemia. To assess the effect of hyperinsulinemia on VLDL secretion in this model, we measured rates of secretion of VLDL in perfuse
Externí odkaz:
https://doaj.org/article/b965049c35d04370b533667cfb56f062